Navigation Links
Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
Date:10/12/2010

FARMINGDALE, N.Y., Oct. 12 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced a definitive agreement to end its non-exclusive distribution arrangement in the United States with Aesculap, Inc. for the SonaStar® Surgical Aspiration System.  

As a result, Misonix will assume exclusive responsibility for the marketing, sales, distribution and service of the SonaStar effective October 18, 2010, utilizing its previously established 75 person sales and service organization, which began direct to hospital marketing of the SonaStar late last year.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

"We are very excited about bringing all domestic sales of SonaStar under our focused sales organization," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Over time, we expect to gain significant margin improvement and sales growth by enabling our proprietary sales organization to sell another one of our key products exclusively under the Misonix label."

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath / Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results
2. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
3. Misonix Announces New Distribution Agreement For Spain
4. Misonix Announces New Distribution Agreement for France
5. Misonix Announces New Distribution Agreement for Russia
6. Misonix Announces New GPO Agreement With First Choice Cooperative
7. Misonix Announces New Distribution Agreement for Mexico
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
10. Misonix Reports First Quarter Fiscal 2010 Financial Results
11. Misonix Announces New Distribution Agreement for Argentina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
Breaking Medicine Technology:
(Date:5/4/2016)... Providence, Rhode Island (PRWEB) , ... May 04, ... ... was launched in April 2016. SS&A teamed up with one of the top ... This legal information portal contains informative legal articles related to the law firm's ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of ... life forever with a same-day LASIK procedure at Christenbury Eye Center. The ... Jonathan Christenbury performed her surgery the same day as her in-office consultation and eye ...
(Date:5/4/2016)... ... May 04, 2016 , ... Advanced Spine & Sport Medical Rehabilitation Center, which ... is hosting a free seminar on stem cell injections. The seminar is scheduled for ... Sport, 4601 Telephone Road, Suite 110, Ventura, CA. There are only 10 seats available. ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... powerful cellular therapy software application that helps blood and marrow transplant (BMT) programs ... Transtem’s initial launch, Mediware has continued to enhance core application features. These enhancements ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on Obesity ... 25-27, 2016 at Las Vegas. It aims to bring together academicians, scientists, dietitians, ... research organizations across the globe; making the conference a perfect platform to share ...
Breaking Medicine News(10 mins):